Immunohistochemical molecular phenotypes of gastric cancer based on SOX2 and CDX2 predict patient outcome

BMC Cancer

Volumn 14, Issue 1, 2014, Pages

  Camilo, Vânia ^a   Barros, Rita ^a   Celestino, Ricardo ^a,b   Castro, Patrícia ^a   Vieira, Joana ^c   Teixeira, Manuel R ^a,c   Carneiro, Fátima ^a,d,e   Pinto de Sousa, João ^a,d   David, Leonor ^a,d   Almeida, Raquel ^a,d  

^a UNIVERSITY OF PORTO   (Portugal)

^b POLYTECHNIC INSTITUTE OF PORTO   (Portugal)

^c PORTUGUESE ONCOLOGY INSTITUTE   (Portugal)

^d University of Porto   (Portugal)

^e HOSPITAL DE SÃO JOÃO   (Portugal)

Author keywords

CDX2; Gastric cancer; Prognosis; SOX2; Survival

Indexed keywords

MUCIN 2; MUCIN 5AC; TRANSCRIPTION FACTOR CDX2; TRANSCRIPTION FACTOR SOX2; CDX2 PROTEIN, HUMAN; HOMEODOMAIN PROTEIN; SOX2 PROTEIN, HUMAN; TRANSCRIPTION FACTOR SOX; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER PATIENT; CANCER PROGNOSIS; CANCER STAGING; CANCER SURVIVAL; CONTROLLED STUDY; COPY NUMBER VARIATION; FEMALE; FOLLOW UP; GENDER; GENE AMPLIFICATION; GENE LOCUS; GENOMIC INSTABILITY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHENOTYPE; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STOMACH CANCER; SURVIVAL ANALYSIS; SURVIVAL PREDICTION; TUMOR INVASION; ADENOCARCINOMA; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; STOMACH NEOPLASMS; TREATMENT OUTCOME; VERY ELDERLY; YOUNG ADULT;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; DNA COPY NUMBER VARIATIONS; FEMALE; GENE AMPLIFICATION; HOMEODOMAIN PROTEINS; HUMANS; IMMUNOHISTOCHEMISTRY; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; PHENOTYPE; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; RETROSPECTIVE STUDIES; SOXB1 TRANSCRIPTION FACTORS; STOMACH NEOPLASMS; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84935505045     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/1471-2407-14-753     Document Type: Article

References (37)

1. Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray F: GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. Lyon, France: International Agency for Research on Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on 27/03/2014.
2. Laurén P: The two histological main types of gastric carcinoma: diffuse and so-called intestinal-type carcinoma. Acta Pathol Microbiol Scand 1965, 64:31-49.
3. Correa P: Human gastric carcinogenesis: a multistep and multifactorial process-First American Cancer Society Award Lecture on Cancer Epidemiology and Prevention. Cancer Res 1992, 52:6735-6740.
4. De Angelis R, Sant M, Coleman MP, Francisci S, Baili P, Pierannunzio D, Trama A, Visser O, Brenner H, Ardanaz E, Bielska-Lasota M, Engholm G, Nennecke A, Siesling S, Berrino F, Capocaccia R, EUROCARE-5 Working Group: Cancer Survival in Europe 1999-2007 by country and age: results of EUROCARE-5- a population-based study. Lancet Oncol 2014, 15:23-34.
5. Allum WH, Blazeby JM, Griffin SM, Cunningham D, Jankowski JA, Wong R: Association of Upper Gastrointestinal Surgeons of Great Britain and Ireland, the British Society of Gastroenterology and the British Association of Surgical Oncology. Gut 2011, 60:1449-1472.
6. Park DI, Yun JW, Park JH, Oh SJ, Kim HJ, Cho YK, Sohn CI, Jeon WK, Kim BI, Yoo CH, Son BH, Cho EY, Chae SW, Kim EJ, Sohn JH, Ryu SH, Sepulveda AR: HER-2/neu amplification is an independent prognostic factor in gastric cancer. Dig Dis Sci 2006, 51:1371-1379.
7. Camilo V, Barros R, Sousa S, Magalhães AM, Lopes T, Santos MA, Pereira T, Figueiredo C, David L, Almeida R: Helicobacter pylori and the BMP pathway regulates CDX2 and SOX2 expression in gastric cells. Carcinogenesis 2012, 33:1985-1992.
8. Beck F, Chawengsaksophak K, Waring P, Playford RJ, Furness JB: Reprogramming of the intestinal differentiation and intercalary regeneration in Cdx2 mutant mice. Proc Natl Acad Sci U S A 1999, 96:7318-7323.
9. Silberg DG, Sullivan J, Kang E, Swain GP, Moffett J, Sund NJ, Sackett SD, Kaestner KH: Cdx2 ectopic expression induces gastric intestinal metaplasia in transgenic mice. Gastroenterology 2002, 122:689-696.
10. Barros R, Freund JN, David L, Almeida R: Intestinal metaplasia revisited: function and regulation of CDX2. Trends Mol Med 2012, 18:555-563.
11. Rugge M, Ingravallo G, Farinati F, Russo VM, Zaninotto G, Alvisi V: CDX2 homeotic gene expression in gastric noninvasive neoplasia. Am J Surg Pathol 2004, 28:834-835.
12. Avilion AA, Nicolis SK, Pevny LH, Perez L, Vivian N, Lovell-Badge R: Multipotent cell lineages in early mouse development depend on SOX2 function. Genes Dev 2003, 17:126-140.
13. Sarkar A, Hochedlinger K: The SOX family of transcription factors: versatile regulators of stem and progenitor cell fate. Cell Stem Cell 2013, 12:15-30.
14. Arnold K, Sarkar A, Yram MA, Polo JM, Bronson R, Sengupta S, Seandel M, Geijsen N, Hochedlinger K: SOX2(+) adult stem and progenitor cells are important for tissue regeneration and survival of mice. Cell Stem Cell 2011, 9:317-329.
15. Schmitz M, Temme A, Senner V, Ebner R, Schwind S, Stevanovic S, Wehner R, Schackert G, Schackert HK, Fussel M, Bachmann M, Rieber EP, Weigle B: Identification of SOX2 as a novel glioma-associated antigen and potential target for T cell-based immunotherapy. Br J Cancer 2007, 96:1293-1301.
16. Chen Y, Shi L, Zhang L, Li R, Liang J, Yu W, Sun L, Yang X, Wang Y, Zhang Y, Shang Y: The molecular mechanism governing the oncogenic potential of SOX2 in breast cancer. J Biol Chem 2008, 283:17969-17978.
17. Bass AJ, Watanabe H, Mermel CH, Yu S, Perner S, Verhaak RG, Kim SY, Wardwell L, Tamayo P, Gat-Viks I, Ramos AH, Woo MS, Weir BA, Getz G, Beroukhim R, O'Kelly M, Dutt A, Rozenblatt-Rosen O, Dziunycz P, Komisarof J, Chirieac LR, Lafargue CJ, Scheble V, Wilbertz T, Ma C, Rao S, Nakagawa H, Stairs DB, Lin L, Giordano TJ, et al: SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet 2009, 41:1238-1242.
18. Li XL, Eishi Y, Bai YQ, Sakai H, Akiyama Y, Tani M, Takizawa T, Koike M, Yuasa Y: Expression of the SRY-related HMG box protein SOX2 in human gastric carcinoma. Int J Oncol 2004, 24:257-263.
19. Otsubo T, Akiyama Y, Yanagihara K, Yuasa Y: SOX2 is frequently downregulated in gastric cancers and inhibits cell growth through cell-cycle arrest and apoptosis. Br J Cancer 2008, 98:824-831.
20. Tian T, Zhang Y, Wang S, Zhou J, Xu S: Sox2 enhances the tumorigenicity and chemoresistance of cancer stem-like cells derived from gastric cancer. J Biomed Res 2012, 26:336-345.
21. Cimerman M, Repse S, Jelenc F, Omejc M, Bitenc M, Lamovec J: Comparison of Lauren's, Ming's and WHO histological classifications of gastric cancer as a prognostic factor for operated patients. Int Surg 1994, 79:27-32.
22. Del Casar JM, Corte MD, Alvarez A, Garcia I, Bongera M, González LO, García-Muñiz JL, Allende MT, Astudillo A, Vizoso FJ: Lymphatic and/or blood vessel invasion in gastric cancer: relationship with clinicopathological parameters, biological factors and prognostic significance. J Cancer Res Clin Oncol 2008, 134:153-161.
23. Siewert JR, Böttcher K, Stein HJ, Roder JD: Relevant prognostic factors in gastric cancer: ten-year results of the german gastric cancer study. Ann Surg 1998, 228:449-461.
24. Stolzenburg S, Rots MG, Beltran AS, Rivenbark AG, Yuan X, Qian H, Strahl BD, Blancafort P: Targeted silencing of the oncogenic transcription factor SOX2 in breast cancer. Nucleic Acids Res 2012, 40:6725-6740.
25. Hütz K, Mejías-Luque R, Farsakova K, Ogris M, Krebs S, Anton M, Vieth M, Schüller U, Schneider MR, Blum H, Wagner E, Jung A, Gerhard M: The stem cell factor SOX2 regulates the tumorigenic potential in human gastric cancer cells. Carcinogenesis 2014, doi:10.1093/carcin/bgt410.
26. Alonso MM, Diez-Valle R, Manterola L, Rubio A, Liu D, Cortes-Santiago N, Urquiza L, Jauregi P, Lopez De Munain A, Sampron N: Genetic and epigenetic modifications of Sox2 contribute to the invasive phenotype of malignant gliomas. PLoS One 2011, doi:10.1371/journal.pone.0026740.
27. Han X, Fang X, Lou X, Hua D, Ding W, Foltz G, Hood L, Yuan Y, Lin B: Silencing SOX2 induced a mesenchymal-epithelial transition and its expression predicts liver and lymph node metastasis in CRC patients. PLoS One 2012, doi:10.1371/journal.pone.0041335.
28. Girouard SD, Laga AC, Mihm MC, Scolver RA, Thompson JF, Zhan Q, Widlund HR, Lee CW, Murphy GF: SOX2 contributes to melanoma cell invasion. Lab Invest 2012, 92:362-370.
29. Garraway LA, Sellers WR: Lineage-dependency and lineage-survival oncogenes in human cancer. Nat Rev Cancer 2005, 6:593-602.
30. Asonuma S, Imatani A, Asano N, Oikawa T, Konishi H, Iijima K, Koike T, Ohara S, Shimosegawa T: Helicobacter pylori induces gastric mucosal intestinal metapasia through the inhibition of interleukin-4-mediated HMG box protein Sox2 expression. Am J Physiol Gastrointest Liver Physiol 2009, 297:G312-G322.
31. Tsukamoto T, Mizoshita T, Mihara M, Tanaka H, Takenaka Y, Yamamura Y, Nakamura S, Ushijima T, Tatematsu M: Sox2 expression in human stomach adenocarcinomas with gastric and gastric-and-intestinal-mixed phenotypes. Histopathology 2005, 46:649-658.
32. Herreros-Villanueva M, Zhang JS, Koenig A, Abel EV, Smyrk TC, Bamlet WR, de Narvajas AA, Gomez TS, Simeone DM, Bujanda L, Billadeau DD: SOX2 promotes dedifferentiation and imparts stem cell-like features to pancreatic cancer cells. Oncogenesis 2013, doi:10.1038/oncsis.2013.23.
33. Koizumi Y, Tanaka SI, Mou R, Koganei H, Kokawa A, Kitamura R, Yamauchi H, Ookubo K, Saito T, Tominaga S, Matsumura K, Shimada H, Tsuchida N, Sekihara H: Changes in DNA copy number in primary gastric carcinomas by comparative genomic hybridization. Clin Cancer Res 1997, 3:1067-1076.
34. Takada H, Imoto I, Tsuda H, Sonoda I, Ichikura T, Mochizuki H, Okanoue T, Inazawa J: Screening of DNA copy number aberrations in gastric cancer cell lines by array-based comparative genomic hybridization. Cancer Sci 2005, 96:100-110.
35. Ottini L, Falchetti M, Lupi R, Rizzolo P, Agnese V, Colucci G, Bazan V, Russo A: Patterns of genomic instability in gastric cancer: clinical implications and perspectives. Ann Oncol 2006, 17(Suppl 7):vii97-vii102.
36. Shi J, Yao D, Liu W, Wang N, Lv H, Zhang G, Ji M, Xu L, He N, Shi B, Hou P: Highly frequent PIK3CA amplification is associated with poor prognosis in gastric cancer. BMC Cancer 2012, doi:10.1186/1471-2407-12-50.
37. Justilien V, Walsh MP, Ali SA, Murray NR, Fields AP: The PRKCI and SOX2 oncogenes are coamplified and cooperate to activate hedgehog signaling in lung squamous cell carcinoma. Cancer Cell 2014, 25:139-151.